| Ytd | -79.65% | |
| 1y | -57.75% |
| Open | 3.49 | Prev Close | 3.47 | Low | 3.43 | High | 3.52 | Mkt Cap | 681.79M |
| Vol | 1.66M | Avg Vol | 3.12M | EPS | -1.08 | P/E | N/A | Forward P/E | -4.33 |
| Beta | -1.29 | Short Ratio | 5.75 | Inst. Own | 85.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 4.78 | 200-d Avg | 8.44 | 1yr Est | 19.06 |
WVE News
WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Fre
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) rose 9.3% on Thursday. The company
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) gapped up before the market opened
Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year
Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone
Analysts downgraded Ryder, Warner Bros. Discovery, Arbor Realty, Pershing Square and PepsiCo; Ryder
Analysts downgraded PepsiCo, RLJ Lodging Trust, Braskem.
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance inn
Analysts downgraded Nike, Comcast, Restaurant Brands.
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; pric
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; pr
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Bl
Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far benea
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinic
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinica
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in it
Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensu
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.34) per share which missed the anal
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRN
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmf
Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and l
Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking t
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w
